How about the development of China's pharmaceutical industry?

Major listed companies in the biopharmaceutical industry: At present, the domestic listed companies in the biopharmaceutical industry mainly include Tiantan Bio (600161), Hualan Bio (002007), Zhifei Bio (300122), Kangtai Bio (300601), Watson Bio (300142), Shanghai Lai Shi (002252 ), etc.

The core data of this article: R & D spending, the number of new drug applications listed

China's biopharmaceutical R & D spending cumulative growth in the ring

With the steady progress of health care reform, the traditional sales-oriented expansion model is unsustainable, and domestic pharmaceutical companies are facing an innovative transformation. From 2016 to 2020, the R&D investment of listed biopharmaceutical companies has been expanding. in 2020, the R&D expenditure of China's listed biopharmaceutical companies reached 11.534 billion yuan, a year-on-year increase of 37.10%. in the first half of 2021, the R&D expenditure of China's listed biopharmaceutical companies has reached 6.978 billion yuan, and the full-year R&D expenditure is expected to grow further. Overall, the increase in R & D investment to a certain extent helps to accelerate the transformation of enterprises in the research results of biopharmaceutical products.

China's new drug application listing situation is optimistic, new product research and development is active

From the point of view of the transformation results, China's new drug listing situation is optimistic, from 2017 to 2020, the number of domestically produced new drug applications for listing fluctuates in the trend of change, of which reached a peak of 45 pieces in 2018.In 2019, the Center for Pharmaceutical Review and Acquisition accepts domestically produced Class I Innovative drug listing application 25 pieces (16 varieties), and 43 pieces of listing application in 2020.

Note: Innovative drugs refer to drugs that are uniquely created by enterprises or research institutions, have novel chemical structures as well as new therapeutic uses, and are patented with independent intellectual property rights, which have significant efficacy in targeting specific diseases, improve treatment rates, and prolong the survival period of patients.

From the point of view of activity, the domestic biopharmaceutical companies are more active in research and development activities, due to the outbreak of the new crown in 2020, there are three pharmaceutical companies in the new crown vaccine and testing reagents invested in research and development, and the other pharmaceutical companies to human vaccines, immunoglobulin as the main research direction.

China's innovative drug research and development capacity is stronger, input and output need to be improved

While China's biomedical industry R & D investment as well as the results of the transformation of the more optimistic, but compared with the developed countries, in many indicators of China's innovative drug research and development is still to be improved. Whether it is the R & D investment capacity or output and developed countries have a certain gap. Even compared with a similar level of India, new drug R & D investment there is also a gap.

Currently, the Chinese government attaches more and more importance to the research and development of innovative drugs with independent intellectual property rights, introduced a series of incentives to play a certain effect, but to make China's innovative drug research and development capabilities can continue to improve, the Chinese government should continue to adjust and improve the relevant policies for China's pharmaceutical companies to create a good policy environment for innovative drug research and development.

Note: Strong: ★★★★★, Stronger: ★★★☆, General: ★★★★, Weaker: ★☆☆, Weak: ★, Unstatistical:--

China's Innovative Drugs R & D Trend

Although China's current level of research and development of innovative drugs is still a certain gap from the world's leading countries, in the future, the innovative drug research and development of Chinese pharmaceutical enterprises will continue to improve. there is still a gap, but in the future, given the global leadership of China's pharmaceutical outsourcing industry and the huge market. China has the strength to become a global drug innovation center; and with China's new crown vaccine in the global popularity of the degree of increase, the national planning of biomedicine attaches great importance to the biomedical, China's biomedical industry in the development of innovative drugs in the future can be expected.

The above data refer to the China Biomedical Industry Market Outlook and Investment Strategy Planning Analysis Report by Prospect Industry Research Institute.